Save the Date: DLA Piper's Life Sciences Summit 2024 is taking place in London on November 6. This annual event will gather leaders from the life sciences community and our DLA Piper team to discuss the critical issues and emerging trends facing the sector today and in the future. If you would like to attend, please register your interest using the link below: https://lnkd.in/dVJYA-Ad Marco de Morpurgo, Lisa LeCointe-Cephas, Lyndsey Olivia Hudson, Gareth Stokes, Danny Tobey, M.D., J.D., Nicholas Tyacke, Ellen Scordino, Jeremy Sher, Chris Campbell, Joost Haans, Amadeu Ribeiro, James Clark, Carolyn Bigg, Adam Vause, Karl Buch, Richard Sterneberg, Victoria Rhodes, Andrew Gilbert, Maura Dineen, Kevin Glenn, Sonia de Kondserovsky
Über uns
Our life sciences team comprises lawyers with legal, scientific and medical knowledge who understand the complexity of the business and regulatory environments in which our clients operate.
- Website
-
https://www.linkedin.com/company/dla-piper-life-sciences
External link for DLA Piper Life Sciences Sector
- Industrie
- Juristische Dienstleistungen
Aktualisierungen
-
Bruna Rocha, Juliana Marcondes De Souza and Victoria Cristofaro Martins Leite share an exciting update about the Brazilian health sector! A recent Superior Court of Justine decision challenged Anvisa's regulatory power on drug advertising, emphasizing compliance with federal legislation over normative acts. The ruling may trigger significant changes in pharmaceutical marketing strategies. #HealthSector #Pharmaceuticals #RegulatoryChanges
-
The life sciences sector is undergoing a transformative shift with the integration of wearable technology and 5G connectivity. As we embrace these innovations, it’s crucial to navigate the legal landscape carefully to maximise their potential in healthcare. Tabitha Norris and Petros Nafpliotis share their insights in our latest Cortex blog post. Click the link below to read more.
Wearables and the rise of standard essential patents in the life sciences sector (via Passle)
lifesciences.dlapiper.com
-
Following the publication of our Life Sciences Index 2024, Rebecca Lawrence shares her views on the rise of AI and the ground-breaking developments we can expect in drug research and development. With 36% of survey respondents considering the application of intelligent technology to be a significant strategic priority, we must consider what the future holds for AI in the life sciences field and beyond. Click the link below to read more.
Drug discovery and development in the age of AI (via Passle)
lifesciences.dlapiper.com
-
The AnoxyGen Project is set to revolutionise our understanding of anaerobic bacteria and their biosynthetic pathways, potentially uncovering new active compounds with significant medical, ecological, and biotechnological applications. While natural products hold immense promise, navigating their patentability requires careful consideration. DLA Piper's Tabitha Norris and Georgina Doukanaris highlight the importance of sufficiency and plausibility in patent applications in our latest Cortex article. Click the link below to read more.
An AnoxyGen-eration of new drugs? Natural products and their patentability (via Passle)
lifesciences.dlapiper.com
-
Stay up to date on the latest Life Sciences developments in Italy and gain valuable insights from our team in the latest issue of our newsletter. Covering a wide spectrum of practice areas, highlights include: • Regulatory • WCC/Compliance • IP • Data, Privacy & Cybersecurity • Product Liability • Antitrust Click the link below to read our #LifeSciences #newsletter #DLAPiperItaly
Life Sciences News in Italy: July 2024
lifesciences.dlapiper.com
-
Andrzej Balicki, Ph.D., Jolanta Dąbrowicz, Przemysław Matuszewski and Urszula Grębowska from our team share their latest monthly briefing, covering updates and insights on medicinal products, medical devices, clinical trials, pharmacies, pharmacists and health protection in the Polish market. #lifesciences #poland
Poland - Life Sciences Monthly Brief, July 2024
lifesciences.dlapiper.com
-
DLA Piper Life Sciences Sector reposted this
We've advised MidEuropa on the acquisition of a controlling stake in FAMAR, a well-established pharmaceutical contract development and manufacturing organisation (CDMO), from ECM Partners and Metric Capital Partners. FAMAR is a trusted partner to a diversified blue-chip client base of pharmaceutical companies operating in more than 80 international markets and provides a full-service offering across the CDMO value-chain. A multi-jurisdictional and cross-practice team worked on the transaction and was led by Ed Griffiths, partner and Co-Head of Private Equity, and legal director Danny McMann. The team also comprised of partners Neil Campbell, Jean Paul Dresen, Matt Evans, Marco de Morpurgo, Paula González de Castejón, and Orestis Omran. Click on the link to read more: https://lnkd.in/eMEiiFTS #MergersandAcquisitions
-
-
Greg Bodulovic, Nicholas Tyacke, Alexandra de Zwart and Hazel P. share the latest update regarding Australia's second wave of vaping reforms that have come into effect. As of 1 July 2024, tobacconists, vape shops and convenience stores are no longer able to lawfully supply any type of vaping products (including non-nicotine vaping products). To read the full update, please click on the link below. #Australia #reform
Australia implements further vaping reforms (via Passle)
lifesciences.dlapiper.com
-
Greg Bodulovic, Nicholas Tyacke, Alexandra de Zwart and Hazel P. share an update about recent enforcement actions by the Australian TGA against unlawful advertising of medicinal cannabis products. It's crucial for businesses to adhere to advertising regulations to avoid legal consequences. #TGA #MedicinalCannabis #AdvertisingRegulations
Australia Regulator Cracks Down on Unlawful Advertising of Medicinal Cannabis (via Passle)
lifesciences.dlapiper.com